Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

XBIT

XBiotech Inc

Nov 13 • 04:00PM ET

2.65

-0.12 -4.33 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN VRTX BIIB GILD INCY ILMN NBIX BMRN ALNY

| Held by: VTI VXF BSVO IWC AVSC AVUV MSSM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.96	Insider Own	36.65%	Shs Outstand	30.49M	Perf Week	10.88%
Market Cap	80.79M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	19.31M	Perf Month	4.33%
Enterprise Value	-66.58M	PEG	-	EPS next Q	-	Inst Own	10.34%	Short Float	0.51%	Perf Quarter	-15.87%
Income	-29.16M	P/S	-	EPS this Y	-	Inst Trans	-14.04%	Short Ratio	1.00	Perf Half Y	-11.07%
Sales	0.00M	P/B	0.48	EPS next Y	-	ROA	-15.25%	Short Interest	0.10M	Perf YTD	-32.91%
Book/sh	5.48	P/C	0.55	EPS next 5Y	-	ROE	-16.23%	52W High	7.64 -65.31%	Perf Year	-63.70%
Cash/sh	4.83	P/FCF	-	EPS past 3/5Y	-29.71% -	ROIC	-17.45%	52W Low	2.09 26.79%	Perf 3Y	-25.14%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	16.05% 7.54%	Perf 5Y	-84.17%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	10.83%	Oper. Margin	-	ATR (14)	0.21	Perf 10Y	-78.40%
Dividend Ex-Date	Jul 15, 2021	Quick Ratio	41.78	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	54.26	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	41.78	EPS Q/Q	-19.74%	SMA20	7.57%	Beta	0.75	Target Price	28.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	1.94%	Rel Volume	0.54	Prev Close	2.77
Employees	92	LT Debt/Eq	0.00	Earnings	-	SMA200	-9.72%	Avg Volume	98.91K	Price	2.65
IPO	Apr 15, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	53,365	Change	-4.33%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-14-19	Initiated	Piper Jaffray	Overweight	$13
Apr-21-17	Downgrade	Noble Financial	Buy → Hold	$13
Jun-28-16	Reiterated	Noble Financial	Buy	$24 → $30

Nov-12-25 11:55AM	XBiotech: Q3 Earnings Snapshot (Associated Press Finance) -5.78%
Aug-13-25 02:55PM	XBiotech: Q2 Earnings Snapshot (Associated Press Finance) +5.72%
May-14-25 03:58PM	XBiotech: Q1 Earnings Snapshot (Associated Press Finance)
Jan-14-25 04:37PM	Wolf Haldenstein Adler Freeman and Herz LLP announces that it is investigating XBiotech for potential violations of securities laws (GlobeNewswire)
Dec-23-24 09:00AM	XBiotech Pauses Rheumatology program (GlobeNewswire) -29.47%
02:45PM	Loading…
Aug-12-24 02:45PM	XBiotech: Q2 Earnings Snapshot (Associated Press Finance)
Jun-18-24 11:35AM	XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer (GlobeNewswire) -13.49%
May-13-24 10:53AM	XBIT Stock Earnings: XBiotech Reported Results for Q1 2024 (InvestorPlace)
May-10-24 01:05PM	XBiotech: Q1 Earnings Snapshot (Associated Press Finance)
Mar-18-24 03:53PM	XBIT Stock Earnings: XBiotech Reported Results for Q4 2023 (InvestorPlace) +12.18%
Jan-04-24 09:00AM	XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus (GlobeNewswire)
Nov-14-23 09:00AM	Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis (GlobeNewswire)
Sep-26-23 09:00AM	XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke (GlobeNewswire)
Aug-30-23 09:00AM	XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer (GlobeNewswire)
Aug-08-23 11:47AM	XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial (GlobeNewswire)
11:53AM	Loading…
Jul-25-23 11:53AM	The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable (Simply Wall St.)
Jun-28-23 10:36AM	Here's Why We're Not Too Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Situation (Simply Wall St.)
May-22-23 09:00AM	FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients (GlobeNewswire)
May-17-23 09:00AM	XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares (GlobeNewswire) +29.02%
Apr-17-23 09:00AM	XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke (GlobeNewswire)
Apr-09-23 10:08AM	XBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insiders (Simply Wall St.)
Feb-15-23 09:29AM	The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable (Simply Wall St.)
Jan-19-23 08:02AM	XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-11-22 05:00AM	XBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021) (Simply Wall St.)
Oct-31-22 09:41AM	Insiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the company (Simply Wall St.)
Oct-13-22 12:46PM	XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix Therapy for Colorectal Cancer (GlobeNewswire)
Sep-08-22 08:59AM	XBiotech (NASDAQ:XBIT) shareholders have endured a 73% loss from investing in the stock a year ago (Simply Wall St.)
Aug-12-22 08:38AM	We Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-20-22 09:00AM	XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study (GlobeNewswire)
May-24-22 09:06AM	Could The XBiotech Inc. (NASDAQ:XBIT) Ownership Structure Tell Us Something Useful? (Simply Wall St.) -5.69%
09:00AM	Loading…
Apr-28-22 09:00AM	XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer (GlobeNewswire) +16.44%
Mar-15-22 11:00AM	XBiotech (NASDAQ:XBIT) shareholders have endured a 48% loss from investing in the stock a year ago (Simply Wall St.)
Feb-02-22 09:00AM	XBiotech Inks Clinical Manufacturing Deal (GlobeNewswire)
Jan-26-22 09:50AM	XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ (GlobeNewswire)
Jan-10-22 10:18AM	Moderna CEO talks Omicron booster shots, 2022 COVID-19 vaccine sales forecasts, global vaccination (Yahoo Finance Video)
09:45AM	New COVID-19 vaccine that covers Omicron will be ready in March, Pfizer CEO says (Yahoo Finance Video)
Dec-15-21 10:37AM	Do Insiders Own Lots Of Shares In XBiotech Inc. (NASDAQ:XBIT)? (Simply Wall St.)
Dec-13-21 08:00AM	FDA Approves XBiotechs IND in Rheumatology (GlobeNewswire)
Oct-28-21 11:59AM	XBiotech to Launch Novel Candidate Therapy for Stroke (GlobeNewswire)
Sep-14-21 11:48AM	XBiotech's (NASDAQ:XBIT) investors will be pleased with their fantastic 514% return over the last three years (Simply Wall St.)
Sep-08-21 09:00AM	Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotechs Natrunix Anti-Cancer Therapy in Pancreatic Cancer (GlobeNewswire)
Aug-30-21 09:00AM	XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director (GlobeNewswire)
Jul-30-21 11:03AM	XBiotech Announces Payment of Dividend to Holders of Common Stock (GlobeNewswire)
Jul-06-21 04:30PM	XBiotech Announces Dividend to Holders of Common Stock (GlobeNewswire) +7.41%
Jun-30-21 11:46AM	XBiotech Announces Receipt of $75 Million from Sale of Antibody (GlobeNewswire)
Jun-29-21 08:04AM	Is XBiotech Inc. (XBIT) Going to Burn These Hedge Funds? (Insider Monkey)
Jun-23-21 08:30AM	XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jun-16-21 02:52AM	Shareholders May Not Be So Generous With XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation And Here's Why (Simply Wall St.)
Jun-08-21 03:16PM	Top Biotech Stocks for Q3 2021 (Investopedia)
May-19-21 09:31AM	Here's What XBiotech Inc.'s (NASDAQ:XBIT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
May-03-21 08:00AM	French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotechs New Cancer Drug for Colorectal Cancer (GlobeNewswire)
Apr-19-21 07:08AM	XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer (Benzinga)
04:00AM	FDA Gives Go-Ahead for XBiotechs Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer (GlobeNewswire)
Mar-18-21 07:51AM	We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate (Simply Wall St.)
Feb-26-21 03:26PM	Top Small-Cap Stocks for March 2021 (Investopedia)
Jan-21-21 08:15AM	XBiotech Candidate True Human COVID-19 Therapy Found to Target Highly Infectious Emerging Strain (GlobeNewswire)
Jan-19-21 08:15AM	XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy (GlobeNewswire)
Nov-29-20 08:14PM	Is XBiotech Inc. (XBIT) A Good Stock To Buy? (Insider Monkey)
Nov-19-20 08:15AM	XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail (GlobeNewswire)
Sep-22-20 03:25PM	What Kind Of Shareholders Hold The Majority In XBiotech Inc.'s (NASDAQ:XBIT) Shares? (Simply Wall St.)
Sep-21-20 08:20AM	XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections (GlobeNewswire) -6.03%
Aug-24-20 10:00AM	Here's How I'm Trading XBiotech (TheStreet.com) +6.59%
08:10AM	XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authorization (GlobeNewswire)
Aug-17-20 08:20AM	XBiotech Discovers COVID-19 Candidate Therapy (GlobeNewswire) +12.21%
Jul-22-20 09:20AM	XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1 Therapy (GlobeNewswire) +9.08%
Jul-14-20 09:25AM	XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke (GlobeNewswire) +5.51%
Jun-22-20 02:17PM	Hedge Funds Starting To Get Bullish On XBiotech Inc. (XBIT) (Insider Monkey)
May-01-20 09:25AM	XBiotech Identifies Super Bloods for the Development of a True Human COVID-19 Therapy (GlobeNewswire)
Apr-17-20 08:45PM	Could XBiotechs Convalescent Plasma Program Make a Breakthrough in Treating COVID-19 Patients? (TipRanks)
Apr-14-20 09:15AM	XBiotech Developing Novel True Human Antibody Targeting Interleukin-1alpha (IL-1) (GlobeNewswire)
Apr-03-20 04:53PM	XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients (GlobeNewswire) +5.03% +12.18%
Feb-19-20 08:15AM	XBiotech Announces Final Results of Tender Offer (GlobeNewswire)
Feb-13-20 01:24PM	Corrected Press Release: XBiotech Announces Preliminary Results of Tender Offer (GlobeNewswire) -24.17%
08:15AM	XBiotech Announces Preliminary Results of Tender Offer (GlobeNewswire)
Feb-10-20 03:59PM	$1.35B deal offers vindication, runway for Austin-based XBiotech (American City Business Journals)
Jan-15-20 08:22AM	The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance (Benzinga)
Jan-14-20 08:30AM	XBiotech Commences Tender Offer to Purchase up to $420,000,000 of its Shares (GlobeNewswire) +30.67%
Dec-30-19 04:05PM	XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen (GlobeNewswire)
Dec-20-19 02:53PM	XBiotech Inc. (XBIT): Are Hedge Funds Right About This Stock? (Insider Monkey)
Dec-17-19 08:15AM	XBiotech Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-10-19 07:14AM	Drug manufacturers have spent a record $342 billion on M&A in 2019 (MarketWatch)
Dec-07-19 03:05AM	XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen (GlobeNewswire)
Nov-19-19 08:55AM	XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa (GlobeNewswire) +10.42%
Nov-12-19 08:45AM	XBiotech Announces First Patient Enrolled in Placebo-Controlled Clinical Study Evaluating Its anti-IL-1 Therapy Bermekimab in Patients with Atopic Dermatitis (Eczema) (GlobeNewswire)
Oct-23-19 08:15AM	XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa (GlobeNewswire)
Oct-10-19 02:57PM	XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Oct-02-19 08:59AM	XBiotech Announces First Patient in Clinical Study to Evaluate Bermekimab in Systemic Sclerosis (GlobeNewswire) -8.48%
Sep-27-19 08:15AM	XBiotech Announces Oral Presentation of Atopic Dermatitis Results for Bermekimab at 2019 EADV Congress in Madrid, Spain (GlobeNewswire)
Sep-20-19 08:15AM	XBiotech Announces Granting of Canadian Patent for Treatment of Dermatological Pathologies (GlobeNewswire)
Jul-16-19 01:15PM	What Kind Of Investor Owns Most Of XBiotech Inc. (NASDAQ:XBIT)? (Simply Wall St.)
Jul-11-19 08:30AM	Dr. Seth Forman to Chair XBiotechs Second Phase 2 Study of Bermekimab in Atopic Dermatitis (GlobeNewswire)
Jul-10-19 08:00AM	XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its Corporate Board (GlobeNewswire)
Jul-09-19 08:00AM	Medical Research Council Funds Phase 2 Multi-Center Study of XBiotechs Bermekimab in Advanced Cancer Patients (GlobeNewswire)
Jun-26-19 08:30AM	XBiotech Wins Commercial Real Estate Award for Industrial Development for its Headquarters in Austin, Texas (GlobeNewswire)
Jun-25-19 08:45AM	XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa (GlobeNewswire)
Jun-11-19 08:00AM	XBiotech Added to Russell 3000® Index (GlobeNewswire)
Jun-04-19 04:01PM	XBiotech Announces Closing of Public Offering of Common Shares (GlobeNewswire) -5.57%
May-31-19 08:47AM	XBiotech Announces Pricing of Public Offering of Common Shares (GlobeNewswire) -20.70%
May-30-19 04:32PM	XBiotech Announces Public Offering of Common Shares (GlobeNewswire)
May-23-19 08:20AM	XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa (GlobeNewswire)

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XBIT

XBiotech Inc

Upgrade your FINVIZ experience